Cost-effectiveness evaluation of glucosamine for osteoarthritis based on simulation of individual patient data obtained from aggregated data in published studies.
[en] Background: The economic evaluation of treatments usually requires access to individual patient data, which is difficult to obtain. Moreover, in osteoarthritis, health utility scores are unavailable and can be assessed only using a validated equation model based on various clinical data. We aimed to develop and validate a methodology to simulate individual health utility scores from aggregated clinical data available in published studies to calculate the cost-effectiveness of different glucosamine preparations (i.e., crystalline glucosamine sulfate, glucosamine sulfate, and glucosamine hydrochloride) used for osteoarthritis.
Methods: We developed a method to simulate individual utility values and validated the model by comparing the results obtained with the simulation and the results of one trial where the utility scores are available. Then, we simulated the utility scores of 10 published trials that used different glucosamine preparations. The utility estimates were used to calculate the quality-adjusted life year (QALY) using the area-under-the-curve method. Costs were for the glucosamine product only. The incremental cost/effectiveness ratio (ICER) was then calculated.
Results: The values of utility scores calculated from data sources and those simulated with the model were similar. From 10 studies where utility was simulated, four used crystalline glucosamine sulfate, and six used other formulations. The ICER revealed that compared to placebo, crystalline glucosamine sulfate only was cost-effective at all time points and up to 3 years
with a median ICER of 5347.2 €/QALY at month 3, 4807.2 €/QALY at month 6 and 11535.5 €/QALY at year 3. The use of other formulations was not cost-effective.
Conclusion: Using a new model to simulate individual health utility scores of patients included in ten published trials, ICER analysis showed that the use of crystalline glucosamine sulfate is cost-effective, while other formulations were not. The results confirm the importance of the formulation of glucosamine products.
Disciplines :
General & internal medicine Public health, health care sciences & services
Author, co-author :
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Honvo, Germain ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie clinique
Detilleux, Johann ; Université de Liège - ULiège > Dpt. de gestion vétérinaire des Ressources Animales (DRA) > Génétique quantitative
Language :
English
Title :
Cost-effectiveness evaluation of glucosamine for osteoarthritis based on simulation of individual patient data obtained from aggregated data in published studies.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Vina ER, Kwoh CK (2018) Epidemiology of osteoarthritis: literature update. Curr Opin Rheumatol 30:160–167. 10.1097/BOR.0000000000000479
Hochberg MC, Altman RD, April KT et al (2012) American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 64:465–474
Zhang W, Nuki G, Moskowitz RW et al (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 18:476–499. 10.1016/j.joca.2010.01.013
McAlindon TE, Bannuru RR, Sullivan MC et al (2014) OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 22:363–388. 10.1016/j.joca.2014.01.003
Bruyere O, Cooper C, Pelletier JP et al (2014) An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). Semin Arthritis Rheum 44:253–263. 10.1016/j.semarthrit.2014.05.014
Nelson AE, Allen KD, Golightly YM et al (2014) A systematic review of recommendations and guidelines for the management of osteoarthritis: the chronic osteoarthritis management initiative of the U.S. bone and joint initiative. Semin Arthritis Rheum 43:701–712. 10.1016/j.semarthrit.2013.11.012
Reginster JY, Cooper C, Hochberg M et al (2015) Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. Curr Med Res Opin 31:1041–1045. 10.1185/03007995.2015.1027183
Bruyere O, Cooper C, Al-Daghri NM et al (2018) Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Aging Clin Exp Res 30:111–117. 10.1007/s40520-017-0861-1
Eriksen P, Bartels EM, Altman RD et al (2014) Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken) 66:1844–1855. 10.1002/acr.22376
Hiligsmann M, Cooper C, Arden N et al (2013) Health economics in the field of osteoarthritis: an expert’s consensus paper from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). Semin Arthritis Rheum 43:303–313. 10.1016/j.semarthrit.2013.07.003
Scholtissen S, Bruyere O, Neuprez A et al (2010) Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. Int J Clin Pract 64:756–762. 10.1111/j.1742-1241.2010.02362.x
Black C, Clar C, Henderson R et al (2009) The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation. Health Technol Assess 13:1–148. 10.3310/hta13520
Grootendorst P, Marshall D, Pericak D et al (2007) A model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the knee. J Rheumatol 34:534–542
Reginster JY, Deroisy R, Rovati LC et al (2001) Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357:251–256. 10.1016/S0140-6736(00)03610-2
Pavelka K, Gatterova J, Olejarova M et al (2002) Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 162:2113–2123
Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M et al (2007) Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 56:555–567. 10.1002/art.22371
Giordano N, Fioravanti A, Papakostas P et al (2009) The efficacy and tolerability of glucosamine sulfate in the treatment of knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Curr Ther Res Clin Exp 70:185–196. 10.1016/j.curtheres.2009.05.004
Houpt JB, McMillan R, Wein C et al (1999) Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 26:2423–2430
McAlindon T, Formica M, LaValley M et al (2004) Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomized double-blind controlled trial. Am J Med 117:643–649. 10.1016/j.amjmed.2004.06.023
Cibere J, Kopec JA, Thorne A et al (2004) Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum 51:738–745. 10.1002/art.20697
Clegg DO, Reda DJ, Harris CL et al (2006) Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354:795–808. 10.1056/NEJMoa052771
Frestedt JL, Walsh M, Kuskowski MA et al (2008) A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized controlled pilot trial. Nutr J 7:9. 10.1186/1475-2891-7-9
Chopra A, Saluja M, Tillu G et al (2011) A randomized controlled exploratory evaluation of standardized ayurvedic formulations in symptomatic osteoarthritis knees: a government of India NMITLI project. Evid Based Complement Altern Med 2011:724291. 10.1155/2011/724291
Glick H, Doshi JA, Sonnad SS et al (2015) Economic evaluation in clinical trials. Handbooks in health economic evaluation series, 2nd edn. Oxford University Press, Oxford
Chopra A, Saluja M, Tillu G et al (2012) Comparable efficacy of standardized Ayurveda formulation and hydroxychloroquine sulfate (HCQS) in the treatment of rheumatoid arthritis (RA): a randomized investigator-blind controlled study. Clin Rheumatol 31:259–269. 10.1007/s10067-011-1809-z
Ruchlin HS, Insinga RP (2008) A review of health-utility data for osteoarthritis: implications for clinical trial-based evaluation. Pharmacoeconomics 26:925–935
Bruyere O, Pavelka K, Rovati LC et al (2008) Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage 16:254–260. 10.1016/j.joca.2007.06.011
Reginster JL, Bruyere O, Cooper C (2018) Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms. Ann Rheum Dis 77:e39. 10.1136/annrheumdis-2017-212251
Beaudart C, Biver E, Bruyere O et al (2018) Quality of life assessment in musculo-skeletal health. Aging Clin Exp Res 30:413–418. 10.1007/s40520-017-0794-8
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
